The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, USX and CRBP

In This Article:

NEW YORK, NY / ACCESSWIRE / May 3, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Corcept Therapeutics Incorporated (CORT)
Class Period: August 2, 2017 to February 5, 2019
Lead Plaintiff Deadline: May 13, 2019

According to the complaint, Corcept Therapeutics Incorporated allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company’s sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the CORT lawsuit: http://www.kleinstocklaw.com/pslra-1/corcept-therapeutics-incorporated-loss-submission-form?id=1393&from=1

U.S. Xpress Enterprises, Inc. (USX)
Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018
Lead Plaintiff Deadline: May 10, 2019

The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress’s dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization, driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress’s dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress’s OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress’s insurance claim expense was understated; and (4) U.S. Xpress’s cost per mile for driver wages and independent contractors was exceeding the Company’s internal expectations.

Get additional information about the USX lawsuit: http://www.kleinstocklaw.com/pslra-1/u-s-xpress-enterprises-inc-loss-submission-form?id=1393&from=1

Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 to February 28, 2019
Lead Plaintiff Deadline: May 13, 2019